Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1975 Jan;51(591):35–37. doi: 10.1136/pgmj.51.591.35

Treatment of an adrenal cortical carcinoma with a combination of o,p′-DDD and aminoglutethimide

R D M Scott
PMCID: PMC2495686  PMID: 1161676

Abstract

A patient with Cushing's syndrome due to an adrenocortical carcinoma is described. Treatment of residual disease and functional metastases was attempted with o,p′-DDD and later aminoglutethimide. Aminoglutethimide in a daily dose of 1 g appeared to have little effect additional to o,p′-DDD. It is important to maintain replacement therapy with cortico-steroids throughout the use of these drugs.

Full text

PDF
35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bochner F., Lloyd H. M., Roeser H. P., Thomas M. J. Effects of O,p'DDD and aminoglutethimide on metastatic adrenocortical carcinoma. Med J Aust. 1969 Apr 19;1(16):809–812. [PubMed] [Google Scholar]
  2. Cash R., Brough A. J., Cohen M. N., Satoh P. S. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab. 1967 Sep;27(9):1239–1248. doi: 10.1210/jcem-27-9-1239. [DOI] [PubMed] [Google Scholar]
  3. Fishman L. M., Liddle G. W., Island D. P., Fleischer N., Küchel O. Effects of amino-glutethimide on adrenal function in man. J Clin Endocrinol Metab. 1967 Apr;27(4):481–490. doi: 10.1210/jcem-27-4-481. [DOI] [PubMed] [Google Scholar]
  4. Helson L., Wollner N., Murphy M. L., Schwartz M. K. Metastatic adrenal cortical carcinoma: biochemical changes accompanying clinical regression during therapy with o,p'-DDD. Clin Chem. 1971 Dec;17(12):1191–1193. [PubMed] [Google Scholar]
  5. Hutter A. M., Jr, Kayhoe D. E. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med. 1966 Oct;41(4):572–580. doi: 10.1016/0002-9343(66)90219-1. [DOI] [PubMed] [Google Scholar]
  6. Hutter A. M., Jr, Kayhoe D. E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966 Oct;41(4):581–592. doi: 10.1016/0002-9343(66)90220-8. [DOI] [PubMed] [Google Scholar]
  7. Philbert M., Laudat M. H., Laudat P., Bricaire H. Etude clinique et biologique d'un inhibiteur de l'hormonosynthèse cortisocurrénale: l'aminoglutéthimide. Ann Endocrinol (Paris) 1968 Mar-Apr;29(2):189–210. [PubMed] [Google Scholar]
  8. Rallison M. L., Kumagai L. F., Tyler F. H. Goitrous hypothyroidism induced by amino-glutethimide, anticonvulsant drug. J Clin Endocrinol Metab. 1967 Feb;27(2):265–272. doi: 10.1210/jcem-27-2-265. [DOI] [PubMed] [Google Scholar]
  9. Schteingart D. E., Conn J. W. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab. 1967 Dec;27(12):1657–1666. doi: 10.1210/jcem-27-12-1657. [DOI] [PubMed] [Google Scholar]
  10. Temple T. E., Jr, Jones D. J., Jr, Liddle G. W., Dexter R. N. Treatment of Cushing's disease. Correction of hypercortisolism by o,p'DDD without induction of aldosterone deficiency. N Engl J Med. 1969 Oct 9;281(15):801–805. doi: 10.1056/NEJM196910092811501. [DOI] [PubMed] [Google Scholar]
  11. Thorn G. W., Lauler D. P. Clinical therapeutics of adrenal disorders. Am J Med. 1972 Nov;53(5):673–684. doi: 10.1016/0002-9343(72)90162-3. [DOI] [PubMed] [Google Scholar]
  12. VILAR O., TULLNER W. W. Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology. 1959 Jul;65(1):80–86. doi: 10.1210/endo-65-1-80. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES